UK rates of obesity increased by 92% over two decades
November 13, 2017Research and Development, Sales and Marketing OECD, biotech, drugs, obesity, pharma, pharmaceutical
A recent report by the OECD shares concerns that the UK’s overall health looks set to face a crisis due …
Nigerian agency strongly contests that 70% of drugs are fake
November 13, 2017Manufacturing and Production, Sales and Marketing Nigeria, biotech, drugs, pharma, pharmaceutical, pwC
Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in West Africa, Andrew Nevin, that …
Top Ten most popular articles on Pharmafile.com this week
November 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top ten
Friday again, and we bring you the most read articles on our site this week – one of which was …
Hep-B vaccine four-year battle for FDA approval is finally won
November 10, 2017Medical Communications, Sales and Marketing biotech, drugs, dynavax, hepatitis B, pharma, pharmaceutical
Dynavax had said it was the last throw of the dice for its hepatitis B vaccine, Hepislav-B – the data …
Sanofi signs $805 million deal for MS drug
November 10, 2017Medical Communications, Sales and Marketing Principia Biopharma, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate …
Breast cancer recurrence can occur up to 20 years after treatment, report shows
November 10, 2017Medical Communications, Research and Development Cancer, breast cancer, pharma, tamoxifen
New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …
Sage scores good but not great P3 postpartum depression drug results
November 10, 2017Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical
Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …
Recipharm Interim report January – September 2017
November 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Interim report January – September 2017 July – September 2017
Recipharm to end operations in two facilities in Sweden
November 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Recipharm today announces that it will initiate a process with the intention of discontinuing manufacturing operations at its facilities in …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
Gene therapy helps child regrow 80% of skin
November 9, 2017Medical Communications, Research and Development biotech, drugs, gene therapy, pharma, pharmaceutical, stem cell
A young child has been brought back from the verge of death after an experimental combination of stem cell and …
Seqirus announces £40m UK fill-and-finish flu vaccine facility
November 9, 2017Manufacturing and Production Liverppol, Novartis, UK, Vaccine, flu, influenza, pharma, seqirus
Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …
NHS Chief in high-stakes gambit to boost funding in autumn budget
November 9, 2017Medical Communications NHS, biotech, drugs, pharma, pharmaceutical
It speaks to the desperation of the funding crisis for the NHS that Chief Executive of the NHS, Simon Stevens, …
GSK indicates a return to oncology by appointing Roche veteran
November 9, 2017Medical Communications GSK, Hal Barron, biotech, drugs, pharma, pharmaceutical
GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and …
17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows
November 8, 2017Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer
At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …
The End Game: Payer Engagement Webinar
November 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, biotech, drugs, pharma, pharmaceutical
In our latest free to attend webinar, we have joined up with NDA to bring you the latest market access …
Cellectis given another shot at off-the-shelf CAR-T
November 8, 2017Medical Communications, Research and Development CAR-T, biotech, cellectis, drugs, pharma, pharmaceutical
It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …
Clinical trials still have a problem with ethnic minorities
November 8, 2017Medical Communications, Research and Development biotech, clinical trials, drugs, ethnic minorities, pharma, pharmaceutical
Research, published in the Journal of Women’s Health, that aimed to determine the effects of the FDA’s guidance on the …
Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time
November 8, 2017Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …
Collaboration in Biopharma
November 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical
Dear Colleague,
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
